Patents Assigned to Athergen, Inc.
  • Composition comprising nicotinamide mononucleotide and leucomethylene blue
    Patent number: 12410394
    Abstract: A cell reprogramming composition and method wherein the composition includes a base molecule, ?-nicotinamide mononucleotide, trichostatin A and zwitterionic liposomes and wherein the method includes receiving a cell and reprogramming agents, wherein the reprogramming agents comprise Oct-4, Sox 2 and Klf4, to reprogram the cell to an embryonic state.
    Type: Grant
    Filed: January 6, 2023
    Date of Patent: September 9, 2025
    Assignee: Athergen, Inc.
    Inventor: Joseph Chalifoux